Research programme: melanocortin-4 receptor agonists - Melacure TherapeuticsAlternative Names: melanocortin-4 receptor agonists research programme - Melacure Therapeutics
Latest Information Update: 02 Aug 2006
At a glance
- Originator Melacure Therapeutics (CEASED)
- Mechanism of Action Melanocortin type 4 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 02 Aug 2006 No development reported - Preclinical for Diabetes mellitus in Sweden (unspecified route)
- 02 Aug 2006 No development reported - Preclinical for Obesity in Sweden (unspecified route)
- 17 Jul 2003 Preclinical trials in Diabetes mellitus in Sweden (unspecified route)